MaRS Discovery District, Toronto, ON; December 14, 2020 – Proteocyte AI, a personalized medicine and diagnostics company located in MaRS Centre, Toronto, ON, announces today that Oral Cancer and the Race Against Time: Use of Psoriasin (S100A7) as a Predictive Marker to Enhance Assessment of Cancer Risk in Oral Lesions published today in Oral Health, recognizes that the addition of prognostic biomarkers (like S100A7) to the diagnostic toolkit could ultimately guide clinicians to a more confident and supported treatment plan, favouring early detection and preventive action.
Dr. Mark Darling, professor in Pathology at Western University (London, ON) and the senior author of the article says: “Future implementation of Straticyte™ into the clinical risk assessment of suspicious oral lesions could be used to complement current methods of traditional dysplasia grading. The combined evaluation of multiple preneoplastic components (including Straticyte) could provide a more holistic, objective, and assured assessment of oral cancer risk, to better guide treatment. Incorporation of prognostic biomarker tests, like Straticyte, is on the imminent horizon, with great potential to heighten early cancer detection and improve patient outcomes.”
The article can be viewed here.
Proteocyte AI is a personalized medicine and diagnostics company located in MaRS Center, Toronto, ON. Proteocyte’s products help tackle the uncertainty surrounding oral cancer care, one of the most aggressive human cancers. The company’s oral dysplasia predictive test, Straticyte, was developed from a panel of 811 protein biomarkers, leverages over 10 years of R&D, and is positioned to disrupt oral dysplasia and cancer care worldwide.